Conservative possibilities influencing PCOS syndrome – the importance of nutrition

2021 ◽  
Vol 86 (5) ◽  
pp. 343-348
Author(s):  
Dávid Líška ◽  
◽  
Jozef Záhumenský

Polycystic ovary syndrome (PCOS) is a common pathological condition in women. Conservative treatment is used in the treatment of polycystic ovary syndrome. Conservative treatment options include increased physical activity and diet. The main aim of the article is to discuss the therapeutic treatment of infl uencing PCOS from a nutritional point of view. PCOS is associated with several comorbidities, including infertility, metabolic syndrome, obesity, impaired glucose tolerance, diabetes mellitus II, and increased cardiovascular risk. Several therapeutic diets can be used in the treatment of PCOS, such as the DASH diet, the low-carbohydrate diet, and a diet based on a low glycemic index. A change in eating habits is associated with improvement in PCOS symptoms. Key words: polycystic ovary syndrome – nutrition – diet – metabolic syndrome

2020 ◽  
Vol 80 (02) ◽  
pp. 161-171 ◽  
Author(s):  
Xiaoxuan Zhao ◽  
Yuepeng Jiang ◽  
Hongyan Xi ◽  
Lu Chen ◽  
Xiaoling Feng

AbstractPolycystic ovary syndrome (PCOS) is an endocrine and metabolic syndrome (MS) with a complex etiology, and its pathogenesis is not yet clear. In recent years, the correlation between gut microbiota (GM) and metabolic disease has become a hot topic in research, leading to a number of new ideas about the etiology and pathological mechanisms of PCOS. The literature shows that GM can cause insulin resistance, hyperandrogenism, chronic inflammation and metabolic syndrome (obesity, diabetes) and may contribute to the development of PCOS by influencing energy absorption, the pathways of short chain fatty acids (SCFA), lipopolysaccharides, choline and bile acids, intestinal permeability and the brain–gut axis. As part of the treatment of PCOS, fecal microbiota transplantation, supplementation with prebiotics and traditional Chinese medicine can be used to regulate GM and treat disorders. This article reviews possible mechanisms and treatment options for PCOS, based on methods which target the GM, and offers new ideas for the treatment of PCOS.


2013 ◽  
Author(s):  
Antic Ivana Bozic ◽  
Jelica Bjekic-Macut ◽  
Dimitrios Panidis ◽  
Danijela Vojnovic Milutinovic ◽  
Biljana Kastratovic ◽  
...  

2014 ◽  
Author(s):  
Ivana Bozic Antic ◽  
Djuro Macut ◽  
Jelica Bjekic-Macut ◽  
Danijela Vojnovic Milutinovic ◽  
Milan Petakov ◽  
...  

2011 ◽  
Vol 96 (5) ◽  
pp. 1271-1274 ◽  
Author(s):  
Miriam Hudecova ◽  
Jan Holte ◽  
Matts Olovsson ◽  
Anders Larsson ◽  
Christian Berne ◽  
...  

Circulation ◽  
2021 ◽  
Vol 143 (Suppl_1) ◽  
Author(s):  
Hridya C Rao ◽  
Lindsay Fernandez-Rhodes ◽  
Michelle Meyer ◽  
Michelle Kominiarek ◽  
Linda Gallo ◽  
...  

Introduction: Polycystic Ovary Syndrome (PCOS) is associated with increased Metabolic Syndrome (MetS), however, these findings have not been characterized in Hispanic/Latina women who are disproportionately burdened by obesity and cardiovascular disease risk compared to non-Hispanic whites. It is also unclear if this association is moderated by elevated high-sensitivity C-Reactive Protein (hs-CRP) levels, a marker for inflammation and a predictor of cardiovascular disease. Hypothesis: In Hispanic/Latina women, we hypothesized that 1) PCOS (self-reported diagnosis and signs) is associated with a higher prevalence of MetS compared to those not reporting PCOS 2) elevated hs-CRP is associated with MetS, and 3) the PCOS-MetS association is moderated by elevated hs-CRP. Methods: We used information from reproductive and economic questionnaires and venous blood measurements collected in Hispanic Community Health Study/Study of Latinos (2008-2017), a U.S. community-based cohort study of Hispanic/Latino adults. PCOS was operationalized as either 1) signs of PCOS (e.g., menstrual cycles >35 days, irregular cycles (at age 20 to 40 years old when not using birth control pills or other hormone medications and not pregnant or breastfeeding) or 2) having answered “yes” to a self-reported question on PCOS. MetS was operationalized as ≥3 elevated subcomponents of MetS (i.e., waist circumference, hypertension, insulin resistance, lipid profile, and triglycerides). A hs-CRP value ≥3.0 mg/L was considered elevated. We adjusted for the complex survey study design, age, study center, Hispanic/Latina background, and age at immigration in all models. Results: The overall (unweighted N=9582) age ranged from 18 to 76 years (mean=41.74, SD=14.18). The prevalence of PCOS (self-reported diagnosis and signs) was 12% (1008/7366), prevalence of MetS was 40% (2380/3495), prevalence of elevated-hsCRP was 44% (3704/4667). PCOS was associated with a significantly higher odds of MetS before (OR 1.35, 95% CI: 1.06-1.71) and after adjusting for elevated-hsCRP (OR 1.29, 95%CI: 1.02-1.65). Elevated hs-CRP is significantly associated with MetS (OR 2.31, 95%CI: 1.95-2.76). There was no significant interaction effect of hs-CRP in the PCOS-MetS association. Conclusions: Prevalence of PCOS (self-reported and signs) was 12% in our sample of Hispanic/Latina women, which is consistent with the previous findings in non-Hispanic whites. Both PCOS (self-reported diagnosis and signs) and elevated hs-CRP were significantly associated with higher prevalence of MetS and could indicate women at metabolic disease risk.


Author(s):  
Anne-Marie Carreau ◽  
Marie-Hélène Pesant ◽  
Jean-Patrice Baillargeon

Sign in / Sign up

Export Citation Format

Share Document